Stefan Weber, CEO, Newron Pharmaceuticals 00:00:00
Newron Pharmaceuticals is focused on the development of its novel schizophrenia drug with two pivotal Phase III trials due to start in Q221. The company already has a marketed product for Parkinson’s disease